Pernix Therapeutics Holdings (PTX) Shares are Up 14.24%

Pernix Therapeutics Holdings (PTX) : Traders are bullish on Pernix Therapeutics Holdings (PTX) as it has outperformed the S&P 500 by a wide margin of 47.38% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 14.27%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 14.24% in the last 1 week, and is up 47.94% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Pernix Therapeutics Holdings, Inc. is up 97.82% in the last 3-month period. Year-to-Date the stock performance stands at -72.31%. The stock has recorded a 20-day Moving Average of 19.9% and the 50-Day Moving Average is 41.53%.


Pernix Therapeutics Holdings (NASDAQ:PTX): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.73 and $0.71 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.92. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.82, notching a gain of 21.91% for the day. The total traded volume was 38,069,393 . The stock had closed at $0.67 on the previous day.

Also, Brokerage firm Brean Capital downgrades its rating on Pernix Therapeutics Holdings (NASDAQ:PTX). The shares have been rated Hold. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on August 12, 2016.

Pernix Therapeutics Holdings, Inc. (Pernix) is a pharmaceutical company. The Company is engaged in the acquisition, development and commercialization of prescription drugs, primarily for the United States market. The Company focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. The Companys products include Treximet, an analgesic indicated for acute migraine; Silenor (doxepin), a prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla (desvenlafaxine extended-release tablets), for major depressive disorder. The Company distributes its generic products through wholly owned subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc. (Cypress).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.